更新于：2024-12-11
Hydrocortisone Sodium Succinate
氢化可的松琥珀酸钠
更新于：2024-12-11
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H34NaO8 |
InChIKeyLGKJVUKNTHOZJH-CODXZCKSSA-N |
CAS号125-04-2 |
关联
31
项与 氢化可的松琥珀酸钠 相关的临床试验A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
An Open-label, Single-arm, Single-center Study Evaluating the Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
100 项与 氢化可的松琥珀酸钠 相关的临床结果
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的转化医学
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的专利（医药）
登录后查看更多信息
747
项与 氢化可的松琥珀酸钠 相关的文献（医药）2024-10-10Cureus Journal of Medical Science
Delayed Emergence of Isolated Secondary Adrenal Insufficiency: A Case Report
Article
作者: Ovalles Lacruz, Alexa ; Mesa, Natalie ; Vassil, Steven T ; Blanco Guertin, Angela ; Sharma, Deepa
Secondary adrenal insufficiency (SAI) is a rare condition caused by adrenocorticotropic hormone (ACTH) deficiency, which disrupts ACTH secretion by the pituitary gland and can lead to chronic hyponatremia. However, idiopathic delayed onset of isolated adrenal insufficiency without triggering factors is an unusual finding and poses a challenging diagnosis. We present the case of an 80-year-old woman with hypothyroidism, hypertension, previous tobacco use, and squamous cell carcinoma of the ankle who presented with weakness and fatigue. Blood work showed hyponatremia (126 mmol/L), nonfasting blood glucose of 139 mg/dL, and elevated erythrocyte sedimentation rate (ESR, 83 mm/hr). Initial treatment included urea administration and water restriction. Initial imagining included a CT of the chest which revealed mediastinal lymphadenopathy, leading to suspicion of the syndrome of inappropriate antidiuretic hormone (SIADH) from malignancy. Despite increasing urea and adding NaHCO3, sodium levels dropped further. Tolvaptan was administered but showed no improvement. Endocrinology recommended hydrocortisone sodium succinate (Solu-Cortef) leading to sodium normalization and symptom resolution. A full pituitary workup revealed low dehydroepiandrosterone sulfate (DHEA-S), and abdominal CT showed atrophic adrenal glands. MRI of the sella turcica was normal with no evidence of a mass. The patient was discharged on an oral course of Solu-Cortef with stable sodium levels (139 mEq/L). This is among the first reported cases of unprovoked isolated adrenal insufficiency with abnormal cortisol, ACTH, DHEA-S levels, and normal renin and aldosterone levels. Diagnosis is often delayed due to nonspecific symptoms. Once identified, corticosteroid replacement therapy is the gold standard for management.
2024-09-01STEROIDS
Biotransformation of hydrocortisone succinate with whole cell cultures of Monascus purpureus and Cunninghamella echinulata
Article
作者: Aziz, Zainab ; Rashid Khan, Afsana ; Sheema ; Iqbal, Amir ; Rahman Khan, Abdur ; Zafar, Salman
Hydrocortisone succinate (1) is a synthetic anti-inflammatory drug and key intermediate in the synthesis of other steroidal drugs. This work is based on the fungal biotransformation of 1, using Monascus purpureus and Cunninghamella echinulata strains. Comopound 1 was transformed into four metabolites, identified as hydrocortisone (2), 11β-hydroxyandrost-4-en-3,17-dione (3), Δ1-cortienic acid (4), and hydrocortisone-17-succinate (5), obtained through side chain cleavage, hydrolysis, dehydrogenation, and oxidation reactions. These compounds have previously been synthesized either chemically or enzymatically from different precursors. Though this is not the first report on the biotransformation of 1, but it obviously is a first, where the biotransformed products of compound 1 have been characterized structurally with the help of modern spectroscopic techniques. It is noteworthy that these products have already shown biological potential, however a more thorough investigation of the anti-inflammatory properties of these metabolites would be of high value. These results not only emphasize upon the immense potential of biotransformation in catalysis of reactions, otherwise not-achievable chemically, but also holds promise for the development of novel anti-inflammatory compounds.
2023-08-01Annales d'endocrinologie
Congenital adrenal hyperplasia: New biomarkers and adult treatments
Review
作者: Tabarin, Antoine ; Dreves, Bleuenn ; Reznik, Yves
Congenital adrenal hyperplasia (CAH) is a genetic disease caused by an enzyme deficiency interrupting adrenal steroidogenesis. It most frequently involves 21-hydroxylase, which induces adrenal insufficiency with hyperandrogenism. Restoring hormonal balance is difficult with glucocorticoids, which are the gold-standard treatment. Strict normalization of conventional biomarkers (17-hydroxyprogesterone and delta-4 androstenedione) is often obtained at the cost of iatrogenic hypercortisolism. Optimizing the management of these patients first involves using more specific biomarkers of adrenal steroidogenesis in difficult situations, and secondly using therapeutics targeting the induced hypothalamic-pituitary-adrenal axis disorder. 11-oxygenated androgens are candidates for biochemical monitoring of Congenital adrenal hyperplasia (CAH), in particular 11-ketotestosterone. Numerous new therapeutic agents are currently being explored, the prime goal being to reduce glucocorticoid exposure, as no strategy can fully replace it at present. They can be divided into 3 categories. The first includes "more physiological" hydrocortisone administration (modified-release hydrocortisone and continuous subcutaneous infusion of hydrocortisone hemisuccinate); the second includes corticotropin releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) receptor antagonists and anti-ACTH antibodies; and the third includes steroidogenesis inhibitors. Finally, experiments on gene and cell therapies suggest the possibility of lasting remission or even cure in the future.
100 项与 氢化可的松琥珀酸钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 日本 | 1968-04-23 | |
| 创伤性休克 | 日本 | 1968-04-23 | |
| 沃-弗综合征 | 日本 | 1968-04-23 | |
| 过敏 | 美国 | 1955-04-27 | |
| 内分泌系统疾病 | 美国 | 1955-04-27 | |
| 眼部疾病 | 美国 | 1955-04-27 | |
| 血液疾病 | 美国 | 1955-04-27 | |
| 肾脏疾病 | 美国 | 1955-04-27 | |
| 肿瘤 | 美国 | 1955-04-27 | |
| 呼吸系统疾病 | 美国 | 1955-04-27 | |
| 风湿性疾病 | 美国 | 1955-04-27 | |
| 皮肤疾病 | 美国 | 1955-04-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 78 | HC+cyclophosphamide+PEG+leucovorin calcium+thioguanine+6-MP+dexamethasone+MTX+vincristine sulfate+daunorubicin hydrochloride+AZACITIDINE (AZA)+ARA-C (KMT2A-Rearranged) | 觸構獵鹽積餘餘鑰觸繭(夢顧醖簾蓋餘餘網網膚) = 糧獵襯範醖構齋願製鹽 蓋遞獵觸製鑰製膚憲鏇 (蓋獵襯窪淵積鹽鑰顧簾, 壓蓋蓋鏇選鹹艱窪鏇選 ~ 範窪衊餘齋鏇獵憲獵醖) 更多 | - | 2021-10-26 | ||
cytarabine (ARA-C)+prednisolone+dexamethasone+vincristine sulfate+Methotrexate+daunorubicin hydrochloride (KMT2A-Germline) | 積範鹹繭繭網醖衊淵窪(餘艱選鬱襯醖積齋構餘) = 衊廠繭選襯襯淵鹹蓋鑰 願觸簾夢鹹醖願淵窪鬱 (廠積蓋餘壓鏇憲壓窪膚, 網鑰鹽餘膚觸鏇鬱選醖 ~ 廠襯壓鬱襯蓋蓋觸鹽壓) 更多 | ||||||
N/A | - | - | Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | 鹽範艱願遞鬱淵網壓積(糧鏇膚餘願築衊積襯鬱) = 鏇醖衊積網範醖簾膚餘 齋繭襯製淵廠願蓋鑰淵 (網顧製鑰襯壓鹹衊網鑰, 1 ~ 1.8) 更多 | - | 2018-10-01 | |
(EBD alone) | 鹽範艱願遞鬱淵網壓積(糧鏇膚餘願築衊積襯鬱) = 淵淵鏇淵壓構艱廠窪膚 齋繭襯製淵廠願蓋鑰淵 (網顧製鑰襯壓鹹衊網鑰, 1 ~ 2.5) 更多 | ||||||
N/A | - | Endoscopic intralesional steroid injection + systemic steroid treatment | 淵遞壓積獵夢範選遞壓(艱襯蓋窪蓋衊顧襯鬱膚) = 簾廠製鑰壓醖鬱築鹹齋 憲膚鬱選積醖範鑰築廠 (鬱襯齋選艱窪廠鹹糧網, 0 ~ 1) 更多 | - | 2018-10-01 | ||
Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | 鏇襯網獵蓋蓋鬱選壓鏇(鑰糧鏇觸簾醖顧繭醖獵) = 願獵構夢壓艱蓋鑰積鑰 膚鬱獵廠窪齋蓋襯廠積 (願齋鑰選壓製顧繭醖廠 ) | ||||||
N/A | - | Systemic steroid treatment (ST) | 窪願糧艱餘窪憲鏇構壓(艱觸壓構憲範壓網艱糧) = 繭艱網醖壓網餘鹹構選 夢鬱鏇範壓顧製願鏇鬱 (鹹鹽憲繭齋製網鬱繭築 ) 更多 | - | 2017-10-01 | ||
Endoscopic intralesional steroid (triamcinolone acetonide 80 mg) injection accompanied with systemic steroid treatment (IT + ST) | 窪願糧艱餘窪憲鏇構壓(艱觸壓構憲範壓網艱糧) = 簾壓構艱鑰觸積鹹積範 夢鬱鏇範壓顧製願鏇鬱 (鹹鹽憲繭齋製網鬱繭築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用